Advertisement FDA approves Taro Pharma Imiquimod cream, 5% ANDA - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Taro Pharma Imiquimod cream, 5% ANDA

The US Food and Drug Administration (FDA) has approved Taro Pharmaceutical's abbreviated new drug application (ANDA) of Imiquimod cream, 5%.

The cream is a prescription based pharmaceutical product which indicated for the treatment of actinic keratosis and external genital warts.

Imiquimod cream, 5% is bioequivalent to Graceway Pharmaceuticals’ Aldara cream, 5%.

Taro Pharmaceutical is engaged in discovery, development, manufacturing and marketing of healthcare products.